Logo image of NAUT

NAUTILUS BIOTECHNOLOGY INC (NAUT) Stock Fundamental Analysis

NASDAQ:NAUT - Nasdaq - US63909J1088 - Common Stock - Currency: USD

0.6879  -0.01 (-1.73%)

After market: 0.7015 +0.01 (+1.98%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NAUT. NAUT was compared to 54 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for NAUT as it has an excellent financial health rating, but there are worries on the profitability. NAUT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NAUT has reported negative net income.
In the past year NAUT has reported a negative cash flow from operations.
In the past 5 years NAUT always reported negative net income.
In the past 5 years NAUT always reported negative operating cash flow.
NAUT Yearly Net Income VS EBIT VS OCF VS FCFNAUT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of NAUT (-30.16%) is worse than 74.07% of its industry peers.
The Return On Equity of NAUT (-35.31%) is worse than 64.81% of its industry peers.
Industry RankSector Rank
ROA -30.16%
ROE -35.31%
ROIC N/A
ROA(3y)-22.18%
ROA(5y)-19.51%
ROE(3y)-25.43%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
NAUT Yearly ROA, ROE, ROICNAUT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NAUT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NAUT Yearly Profit, Operating, Gross MarginsNAUT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, NAUT has more shares outstanding
NAUT has more shares outstanding than it did 5 years ago.
NAUT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NAUT Yearly Shares OutstandingNAUT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NAUT Yearly Total Debt VS Total AssetsNAUT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.63, we must say that NAUT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NAUT (-0.63) is worse than 83.33% of its industry peers.
There is no outstanding debt for NAUT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.63
ROIC/WACCN/A
WACCN/A
NAUT Yearly LT Debt VS Equity VS FCFNAUT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

NAUT has a Current Ratio of 17.36. This indicates that NAUT is financially healthy and has no problem in meeting its short term obligations.
NAUT's Current ratio of 17.36 is amongst the best of the industry. NAUT outperforms 98.15% of its industry peers.
NAUT has a Quick Ratio of 17.36. This indicates that NAUT is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 17.36, NAUT belongs to the best of the industry, outperforming 98.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.36
Quick Ratio 17.36
NAUT Yearly Current Assets VS Current LiabilitesNAUT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.14% over the past year.
EPS 1Y (TTM)7.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NAUT will show a decrease in Earnings Per Share. The EPS will decrease by -6.33% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-9.29%
EPS Next 2Y-12.51%
EPS Next 3Y-6.33%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NAUT Yearly Revenue VS EstimatesNAUT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 20M 40M 60M
NAUT Yearly EPS VS EstimatesNAUT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NAUT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NAUT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NAUT Price Earnings VS Forward Price EarningsNAUT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NAUT Per share dataNAUT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

NAUT's earnings are expected to decrease with -6.33% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.51%
EPS Next 3Y-6.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NAUT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NAUTILUS BIOTECHNOLOGY INC

NASDAQ:NAUT (8/19/2025, 8:07:07 PM)

After market: 0.7015 +0.01 (+1.98%)

0.6879

-0.01 (-1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)10-27 2025-10-27/bmo
Inst Owners37.89%
Inst Owner Change-4.77%
Ins Owners32.24%
Ins Owner Change0.33%
Market Cap86.78M
Analysts85
Price Target2.55 (270.69%)
Short Float %0.38%
Short Ratio0.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.17%
Min EPS beat(2)13.06%
Max EPS beat(2)15.27%
EPS beat(4)4
Avg EPS beat(4)16.85%
Min EPS beat(4)13.06%
Max EPS beat(4)22.76%
EPS beat(8)8
Avg EPS beat(8)15.15%
EPS beat(12)12
Avg EPS beat(12)19.74%
EPS beat(16)14
Avg EPS beat(16)4.73%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.38%
PT rev (3m)42.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.15%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.45
P/tB 0.45
EV/EBITDA N/A
EPS(TTM)-0.52
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0
BVpS1.54
TBVpS1.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.16%
ROE -35.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.18%
ROA(5y)-19.51%
ROE(3y)-25.43%
ROE(5y)-22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 88.05%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.36
Quick Ratio 17.36
Altman-Z -0.63
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)143.23%
Cap/Depr(5y)156.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y-9.29%
EPS Next 2Y-12.51%
EPS Next 3Y-6.33%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.24%
EBIT Next 3Y-3.22%
EBIT Next 5Y-1.7%
FCF growth 1Y-20.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.54%
OCF growth 3YN/A
OCF growth 5YN/A